Literature DB >> 18435819

Ocular manifestations in liver transplant recipients with familial amyloid polyneuropathy.

Ola Sandgren1, Daniel Kjellgren, Ole B Suhr.   

Abstract

PURPOSE: To evaluate postoperative ocular involvement in Swedish liver transplant (LT) recipients with familial amyloid polyneuropathy (FAP).
METHODS: Routine ophthalmological examinations were performed in 48 LT recipients, with particular attention given to amyloid deposition in the anterior segment and the vitreous body. Medical records were scrutinized for information regarding neurological impairment at the time of the LT. The diagnosis was secured in all cases by examining for amyloid deposits in biopsy specimens and positive genetic testing for amyloidogenic transthyretin (ATTR) Val30Met mutation.
RESULTS: Six patients (12.5%) developed vitreous opacities within the post-LT observation period. The first opacities were seen 40 months after transplantation, 8 years after the onset of systemic disease. Four patients (8%) developed secondary glaucoma, the first of which was observed 18 months after the procedure and 6.5 years after the onset of disease. Sixteen patients (33%) developed deposits on the anterior surface of the lens. Scalloped pupillary margins were noted in 10 patients (21%).
CONCLUSION: The prevalence of eye complications increases with time after LT and regular follow-up is necessary, especially to disclose the development of glaucoma--a complication with insidious symptoms of which patients are normally unaware.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18435819     DOI: 10.1111/j.1600-0420.2007.01098.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  15 in total

1.  Epileptic seizures as a presentation of central nervous system involvement in TTR Val30Met-FAP.

Authors:  Ana Franco; Carla Bentes; Mamede de Carvalho; Pedro Pereira; José Pimentel; Isabel Conceição
Journal:  J Neurol       Date:  2016-10-11       Impact factor: 4.849

2.  Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.

Authors:  Stephen Connelly; David E Mortenson; Sungwook Choi; Ian A Wilson; Evan T Powers; Jeffery W Kelly; Steven M Johnson
Journal:  Bioorg Med Chem Lett       Date:  2017-05-26       Impact factor: 2.823

3.  Manifestations of transthyretin-related familial amyloidotic polyneuropathy: long-term follow-up of Japanese patients after liver transplantation.

Authors:  Yuki Ohya; Sadahisa Okamoto; Masayoshi Tasaki; Mitsuharu Ueda; Hirofumi Jono; Konen Obayashi; Kazuhisa Takeda; Hideaki Okajima; Katsuhiro Asonuma; Ryuhei Hara; Hidenobu Tanihara; Yukio Ando; Yukihiro Inomata
Journal:  Surg Today       Date:  2011-08-26       Impact factor: 2.549

4.  Recent advances in the treatment of familial amyloid polyneuropathy.

Authors:  David Adams
Journal:  Ther Adv Neurol Disord       Date:  2013-03       Impact factor: 6.570

5.  Gene expression and functional annotation of the human ciliary body epithelia.

Authors:  Sarah F Janssen; Theo G M F Gorgels; Koen Bossers; Jacoline B Ten Brink; Anke H W Essing; Martijn Nagtegaal; Peter J van der Spek; Nomdo M Jansonius; Arthur A B Bergen
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

6.  Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases.

Authors:  João Melo Beirão; Jorge Malheiro; Carolina Lemos; Idalina Beirão; Paulo Costa; Paulo Torres
Journal:  Amyloid       Date:  2015-06-22       Impact factor: 7.141

7.  Long-term outcomes and complications of trabeculectomy for secondary glaucoma in patients with familial amyloidotic polyneuropathy.

Authors:  Takahiro Kawaji; Toshihiro Inoue; Ryuhei Hara; Daisuke Eiki; Yukio Ando; Hidenobu Tanihara
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

8.  Aqueous humor erythropoietin levels in open-angle glaucoma patients with and without TTR V30M familial amyloid polyneuropathy.

Authors:  João M Beirão; Luciana M Moreira; João C Oliveira; Maria J Menéres; Bernardete B Pessoa; Maria E Matos; Paulo P Costa; Paulo A Torres; Idalina B Beirão
Journal:  Mol Vis       Date:  2014-07-02       Impact factor: 2.367

Review 9.  First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy.

Authors:  David Adams; Ole B Suhr; Ernst Hund; Laura Obici; Ivailo Tournev; Josep M Campistol; Michel S Slama; Bouke P Hazenberg; Teresa Coelho
Journal:  Curr Opin Neurol       Date:  2016-02       Impact factor: 5.710

Review 10.  Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.

Authors:  Yoshiki Sekijima; Mitsuharu Ueda; Haruki Koike; Sonoko Misawa; Tomonori Ishii; Yukio Ando
Journal:  Orphanet J Rare Dis       Date:  2018-01-17       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.